Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
We were handed a company that earned a 44% return on equity and $5.9 billion of net income in 2019, and we are looking at a company that will be lucky to clear $2.4 billion in adjusted profit in 2026 on a larger, more leveraged, more acquisition-stuffed balance sheet. That single sentence tells you most of what you need to know about Biogen. This is a business fighting the tide, not riding it. Charlie has a saying that applies squarely here: "Show me the incentive and I'll show you the outcome." The incentive facing every large specialty pharmaceutical company is brutal and unavoidable — patents expire, generics and biosimilars arrive, and revenue that took a decade to build collapses in twenty-four months. The only defense is to run a treadmill: spend shareholder cash, year after year, buying the next franchise before the last one dies.
Recent filings analysed: 10-Q (2026-07-29), 8-K (2026-07-29), 8-K (2026-07-01), 8-K (2026-06-10).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation